NYSE:NAVB Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Navidea Biopharmaceuticals Stock (NYSE:NAVB) Get NAVB alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume7,146 shsMarket Capitalization$10 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Navidea Biopharmaceuticals, Inc. is a biotechnology company focused on precision immunodiagnostic and radiopharmaceutical products. Its research has centered on the Manocept platform, which is designed to target CD206 receptors found on certain macrophages and other immune-system cells. The company’s principal product is Lymphoseek (technetium Tc 99m tilmanocept injection), a diagnostic imaging agent used to help identify and map lymph nodes during the evaluation and surgical treatment of certain cancers. Lymphoseek has received U.S. regulatory approval for lymphatic mapping in patients with breast cancer and melanoma, as well as for patients with head and neck cancer. Navidea has historically pursued additional applications for the Manocept platform in oncology, inflammatory diseases and other conditions involving macrophage activity. The company has worked with commercial and development partners to support the distribution and further development of its products in the United States and international markets. Information about its current operations and leadership may be limited because the company’s business and corporate status have changed over time.AI Generated. May Contain Errors. Read More Receive NAVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAVB Stock News HeadlinesNavidea Biopharmaceuticals, Inc. Files for BankruptcyOctober 8, 2025 | businesswire.comNavidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock SplitMay 21, 2025 | businesswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax AssetsMarch 31, 2025 | businesswire.comNavidea Biopharmaceuticals Inc. (NAVB) Latest Pre Market TradesDecember 23, 2024 | nasdaq.comNavidea Biopharmaceutical (OTC:NAVB) Stock Quotes, Forecast and News SummaryOctober 28, 2024 | benzinga.comNavidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024July 3, 2024 | businesswire.comNavidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024June 20, 2024 | businesswire.comSee More Headlines NAVB Stock Analysis - Frequently Asked Questions How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.60 million. What other stocks do shareholders of Navidea Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Navidea Biopharmaceuticals investors own include Novavax (NVAX), OPKO Health (OPK), Tesla (TSLA), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Agenus (AGEN). Company Calendar Last Earnings11/10/2021Today10/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NAVB CIK810509 Webwww.navidea.com Phone614-793-7500Fax614-793-7522Employees10Year Founded1983Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$8.13 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares100,080,000Free Float56,367,000Market Cap$10 thousand OptionableNo Data Beta1.76 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:NAVB) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
